|
Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.H6 - code c19: review of device manufacturing record history confirmed device met pre-release specifications.H6 - code b20: the device remains implanted and was therefore not available for analysis.No images enabling direct assessment of product performance were returned for evaluation.The ifu was reviewed and the following statement was found to be applicable: complications and adverse events can occur when using any endovascular device.These complications include, but are not limited to: stenosis, thrombosis or occlusion.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 cfr part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
The following was reported from a study: on (b)(6) 2026, a study patient underwent a thoracoabdominal procedure and a gore® excluder® thoracoabdominal branch endoprosthesis (tambe) devices were implanted.During this procedure, gore® viabahn® vbx endoprosthesis (vbx device) devices were implanted in the visceral arteries as branch devices.On (b)(6) 2026, the patient presented with nausea, vomiting, and generalized weakness.Ct angiography (cta) showed a new occlusion of the left renal artery stent and corresponding patchy areas of decreased renal enhancement, and concerning for bilateral renal infarcts.Creatinine on admission 1.69.Bladder scan showed minimal urine despite iv fluid administration.Left renal artery thrombectomy was performed on the same day.The patient had adequate urine output post-operatively.
|